Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 21181 - 21200 out of 485363 entries
Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
---|---|---|---|---|---|---|---|---|
Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 3.6 mg/0.09 mL injection, 0.09 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 4 mg/0.1 mL injection, 0.1 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |
Australia | (S01LA05) aflibercept | Eylea 4 mg/0.1 mL injection, 0.1 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration; Macular Edema; Diabetes Complications | BayerAustraliaLtd |